头颈部癌症患者接受根治性同期放化疗的预处理营养状况与局部区域失败。
Pretreatment nutritional status and locoregional failure of patients with head and neck cancer undergoing definitive concurrent chemoradiation therapy.
机构信息
Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, New York, USA.
出版信息
Head Neck. 2011 Nov;33(11):1561-8. doi: 10.1002/hed.21640. Epub 2010 Dec 15.
Abstract
BACKGROUND
This study was carried out to determine if markers of nutritional status predict for locoregional failure following intensity-modulated radiation therapy (IMRT) with concurrent chemoradiotherapy (CCRT) for squamous cell carcinoma of the head and neck (SCCHN).
METHODS
We performed a retrospective chart review of 78 patients with SCCHN who received definitive CCRT. We compared patient factors, tumor characteristics, and nutritional status indicators between patients with and without locoregional failure.
RESULTS
Fifteen of 78 patients (19%) experienced locoregional failure. Median follow-up for live patients was 38 months. On univariate analysis, pretreatment percentage of ideal body weight (%IBW) (p < .01), pretreatment hemoglobin (p = .04), and treatment duration (p < .01) were significant predictors of failure. On multivariate analysis, pretreatment %IBW (p = .04) and treatment time (p < .01) remained statistically significant.
CONCLUSIONS
Although treatment time is an accepted risk factor for failure, differences in outcome for patients with head and neck cancer undergoing definitive CCRT based on pretreatment %IBW should be examined further.
摘要
背景
本研究旨在确定营养状况标志物是否可预测接受调强放疗（IMRT）联合同期放化疗（CCRT）的头颈部鳞状细胞癌（SCCHN）患者的局部区域失败。
方法
我们对 78 例接受根治性 CCRT 的 SCCHN 患者进行了回顾性图表审查。我们比较了有和无局部区域失败患者的患者因素、肿瘤特征和营养状况指标。
结果
78 例患者中有 15 例（19%）发生局部区域失败。存活患者的中位随访时间为 38 个月。单因素分析显示，治疗前理想体重百分比（%IBW）（p <.01）、治疗前血红蛋白（p =.04）和治疗时间（p <.01）是失败的显著预测因素。多因素分析显示，治疗前%IBW（p =.04）和治疗时间（p <.01）仍然具有统计学意义。
结论
尽管治疗时间是失败的公认危险因素，但基于治疗前%IBW ，接受根治性 CCRT 的头颈部癌症患者的治疗结果存在差异，应进一步研究。
相似文献
1
Pretreatment nutritional status and locoregional failure of patients with head and neck cancer undergoing definitive concurrent chemoradiation therapy.头颈部癌症患者接受根治性同期放化疗的预处理营养状况与局部区域失败。
Head Neck. 2011 Nov;33(11):1561-8. doi: 10.1002/hed.21640. Epub 2010 Dec 15.
2
Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.采用现代放射技术治疗后，局部晚期头颈部鳞状细胞癌患者的治疗失败模式和复发后结局。
JAMA Oncol. 2017 Nov 1;3(11):1487-1494. doi: 10.1001/jamaoncol.2017.0973.
3
Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.西妥昔单抗与铂类同步放化疗用于局部晚期头颈癌的根治性治疗
Head Neck. 2015 Mar;37(3):386-92. doi: 10.1002/hed.23609. Epub 2014 Apr 16.
4
Pretreatment weight status and weight loss among head and neck cancer patients receiving definitive concurrent chemoradiation therapy: implications for nutrition integrated treatment pathways.头颈部癌症患者在接受根治性同期放化疗期间的预处理体重状况和体重减轻：对营养综合治疗途径的影响。
Support Care Cancer. 2013 Oct;21(10):2825-33. doi: 10.1007/s00520-013-1861-0. Epub 2013 Jun 7.
5
Quantification of the effect of treatment duration on local-regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.根治性同期化疗和调强放疗治疗头颈部鳞癌后治疗时间对局部区域失败影响的定量分析。
Head Neck. 2013 May;35(5):684-8. doi: 10.1002/hed.23024. Epub 2012 May 22.
6
Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.对于头颈部鳞状细胞癌，在进行根治性同步化疗和调强放射治疗后，放疗中断超过一周以及血红蛋白水平低（<12 g/dL）是局部区域复发的预测因素。
Am J Clin Oncol. 2009 Dec;32(6):587-91. doi: 10.1097/COC.0b013e3181967dd0.
7
Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck.头颈部高危皮肤鳞状细胞癌的术后同步放化疗
Head Neck. 2015 Jun;37(6):840-5. doi: 10.1002/hed.23684. Epub 2014 Jun 27.
8
IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.调强放疗同步加量推量照射和同期化疗治疗局部晚期头颈部鳞状细胞癌。
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e845-52. doi: 10.1016/j.ijrobp.2010.10.021. Epub 2010 Dec 16.
9
Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy.原发肿瘤体积是接受根治性放化疗的局部晚期头颈部鳞状细胞癌患者临床结局的重要预测因素。
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1823-30. doi: 10.1016/j.ijrobp.2010.10.053. Epub 2011 May 5.
10
Concurrent Radiotherapy With Cetuximab or Platinum-based Chemotherapy for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.西妥昔单抗或铂类化疗同步放疗用于局部晚期头颈部皮肤鳞状细胞癌
Am J Clin Oncol. 2018 Jan;41(1):95-99. doi: 10.1097/COC.0000000000000228.
引用本文的文献
1
Protocol for the SEHNeCa randomised clinical trial assesing Supervised Exercise for Head and Neck Cancer patients.SEHNeCa 随机临床试验方案，评估头颈部癌症患者的监督锻炼。
BMC Cancer. 2023 Mar 24;23(1):271. doi: 10.1186/s12885-023-10718-4.
2
Narrative review of the management of oral mucositis during chemoradiation for head and neck cancer.头颈部癌放化疗期间口腔黏膜炎管理的叙述性综述
Ann Transl Med. 2021 May;9(10):916. doi: 10.21037/atm-20-3931.
3
Matched pair analysis to evaluate weight loss during radiation therapy for head and neck cancer as a prognostic factor for survival.配对分析以评估头颈癌放射治疗期间的体重减轻作为生存的预后因素。
Ann Transl Med. 2021 May;9(10):914. doi: 10.21037/atm-20-4969.
4
Matched pair analysis to evaluate the impact of hospitalization during radiation therapy as an early marker of survival in head and neck cancer patients.配对分析以评估放疗期间住院作为头颈癌患者生存早期标志物的影响。
Oral Oncol. 2020 Jun 16;109:104854. doi: 10.1016/j.oraloncology.2020.104854.
5
Nutritional Counseling for Head and Neck Cancer Patients Undergoing (Chemo) Radiotherapy-A Prospective Randomized Trial.接受（化疗）放疗的头颈癌患者的营养咨询——一项前瞻性随机试验
Front Nutr. 2019 Mar 18;6:22. doi: 10.3389/fnut.2019.00022. eCollection 2019.
6
The impact of dietary regimen compliance on outcomes for HNSCC patients treated with radiation therapy.饮食方案依从性对接受放疗的头颈部鳞癌患者结局的影响。
Support Care Cancer. 2018 Sep;26(9):3307-3313. doi: 10.1007/s00520-018-4198-x. Epub 2018 Apr 18.
7
Hesperidin as Radioprotector against Radiation-induced Lung Damage in Rat: A Histopathological Study.橙皮苷对大鼠辐射诱导的肺损伤的辐射防护作用：一项组织病理学研究。
J Med Phys. 2017 Jan-Mar;42(1):25-32. doi: 10.4103/jmp.JMP_119_16.
8
Nutrition support and dietary interventions for patients with lung cancer: current insights.肺癌患者的营养支持与饮食干预：当前见解
Lung Cancer (Auckl). 2016 Jan 27;7:1-9. doi: 10.2147/LCTT.S85347. eCollection 2016.
9
Role of comorbidity on outcome of head and neck cancer: a population-based study in Thuringia, Germany.合并症对头颈部癌症预后的作用：德国图林根州的一项基于人群的研究。
Cancer Med. 2016 Nov;5(11):3260-3271. doi: 10.1002/cam4.882. Epub 2016 Oct 11.
10
NRS-2002 for pre-treatment nutritional risk screening and nutritional status assessment in head and neck cancer patients.用于头颈部癌症患者治疗前营养风险筛查和营养状况评估的NRS-2002。
Support Care Cancer. 2015 Jun;23(6):1495-502. doi: 10.1007/s00520-014-2500-0. Epub 2014 Nov 5.
本文引用的文献
1
Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.对于头颈部鳞状细胞癌，在进行根治性同步化疗和调强放射治疗后，放疗中断超过一周以及血红蛋白水平低（<12 g/dL）是局部区域复发的预测因素。
Am J Clin Oncol. 2009 Dec;32(6):587-91. doi: 10.1097/COC.0b013e3181967dd0.
2
Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.对癌症患者促红细胞生成素刺激剂风险的持续重新评估。
Clin Cancer Res. 2008 Jun 1;14(11):3242-7. doi: 10.1158/1078-0432.CCR-07-1872.
3
Influence of weight loss on outcomes in patients with head and neck cancer undergoing concomitant chemoradiotherapy.体重减轻对接受同步放化疗的头颈癌患者预后的影响。
Head Neck. 2008 Apr;30(4):503-8. doi: 10.1002/hed.20737.
4
Nutritional support during radiotherapy for head and neck cancer: the role of prophylactic feeding tube placement.头颈部癌放疗期间的营养支持：预防性放置饲管的作用。
Clin J Oncol Nurs. 2007 Dec;11(6):875-80. doi: 10.1188/07.CJON.875-880.
5
Locally advanced stage IV squamous cell carcinoma of the head and neck: impact of pre-radiotherapy hemoglobin level and interruptions during radiotherapy.局部晚期头颈部IV期鳞状细胞癌：放疗前血红蛋白水平及放疗期间中断治疗的影响
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1108-14. doi: 10.1016/j.ijrobp.2007.07.2380. Epub 2007 Oct 1.
6
Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03).头颈部癌症贫血患者接受或不接受促红细胞生成素的放射治疗：放射治疗肿瘤学组的一项随机试验（RTOG 99-03）
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1008-17. doi: 10.1016/j.ijrobp.2007.04.063. Epub 2007 Aug 23.
7
Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer.基线营养状况可预测局部晚期食管癌患者接受根治性放化疗后的治疗反应和生存情况。
Am J Gastroenterol. 2007 Nov;102(11):2557-63. doi: 10.1111/j.1572-0241.2007.01437.x. Epub 2006 Aug 4.
8
Effect of oral nutritional supplementation on weight loss and percutaneous endoscopic gastrostomy tube rates in patients treated with radiotherapy for oropharyngeal carcinoma.口服营养补充对接受口咽癌放疗患者体重减轻及经皮内镜下胃造口管置入率的影响。
Support Care Cancer. 2008 Mar;16(3):285-9. doi: 10.1007/s00520-007-0313-0. Epub 2007 Aug 7.
9
Cancer cachexia syndrome in head and neck cancer patients: Part II. Pathophysiology.头颈癌患者的癌症恶病质综合征：第二部分。病理生理学。
Head Neck. 2007 May;29(5):497-507. doi: 10.1002/hed.20630.
10
Cancer cachexia syndrome in head and neck cancer patients: part I. Diagnosis, impact on quality of life and survival, and treatment.头颈部癌症患者的癌症恶病质综合征：第一部分。诊断、对生活质量和生存的影响以及治疗。
Head Neck. 2007 Apr;29(4):401-11. doi: 10.1002/hed.20447.
Zotero 插件